 Illinois 17 inhibitors, including Sikukinumab, Brodylumab and Igzikizumab, have been FDA approved for psoriasis treatment and may also be used off-label to treat other inflammatory skin conditions such as hydrodinitis suprativa, piteriasis rubra pilaris, Bessitz disease, alopecia areata, and allergic contact dermatitis. However, more clinical trial data is needed to assess the safety and efficacy of Illinois 17 inhibitors for these conditions. This article was authored by Kevin Kaewoo and Harry Dow.